In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a ...

Roche's Q4 results and innovative advancements make it a strong pick. Its late-stage pipeline supports our belief that there ...

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...

Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investing.com -- Roche's experimental Parkinson's disease drug, prasinezumab, failed to meet its primary objective in a mid-stage trial. The Swiss pharmaceutical ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow. 1 These patients may now be ...

In this article, we are going to take a look at where Roche Holding AG (OTC:RHHVF) stands against Morgan Stanley's other European AI stocks. In August last year, investment bank Morgan Stanley ...